Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis

NCT01935856 ↗

Phase 1/2 Completed 20 enrolled Kyowa Kirin, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after single and multiple administration of KHK7580 for secondary hyperparathyroidism in patients receiving hemodialysis

Timeline

Start: 2013-08
Primary completion: 2014-03
Completion: 2014-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EVOCALCET	Small molecule	—	Oral

Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis

Summary

Timeline

Drugs

Indications